- Q85.89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2024 edition of ICD-10-CM Q85.89 became effective on October 1, 2022.
- This is the American ICD-10-CM version of Q85.89 – other international versions of ICD-10 Q85.89 may differ.
ICD-10-CM Q85.89 is grouped within Diagnostic Related Group(s):
- 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures with mcc
- 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures with cc
- 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures without cc/mcc
- 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
- 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
- 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
- 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
- 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc
Applicable To
- Peutz-Jeghers syndrome
- Sturge-Weber(-Dimitri) syndrome
Code History
- 2024 (effective 10/1/2022): New code
- 2024 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to Q85.89:
- encephalotrigeminal > Angiomatosis Q82.8
- specified NEC > Phakomatosis Q85.9
- Peutz-Jeghers > Syndrome
- Sturge-Weber (-Dimitri) > Syndrome